摘要
目的探讨新一代非典型抗精神病药博思清(阿立哌唑)对精神分裂症患者的疗效及生活质量的影响。方法对符合CCMD-3精神分裂症诊断标准的患者进行博思清单一治疗12周,应用简明精神病量表(BPRS)、阴性症状量表(SANS)、副反应量表(TESS)、世界卫生组织编制的生活质量量表(QOL-100)观察疗效、副反应和生活质量的变化,并做治疗前后的自身对照研究。结果治疗后BPRS及SANS各因子分均较治疗前明显减低,差异显著。TESS量表以头痛、激越、失眠、嗜睡、恶心等多见。生活质量除精神支柱领域外其它领域均较治疗前有显著提高。结论博思清治疗精神分裂症疗效优越,副作用少,可替代传统抗精神病药物的治疗。
Objective To approach the effect of DSSs to schizophrenic curative effect and quality of life. Methods To treat schizophrenia 12 weeks that fitting CCMD-3 diagnostic code with single aripiprazole. Applicating BPRS, SANS, TESS and WHO QOL-100 lists to observe the curative effect, adverse reaction, quality of life, and to do own control study of anteroposterior treatment. Results The score of all factors reduced after treatment, having singnificant deviation. Headache, agitate, insomnia, lethargy, nausea are more to meet. All spleres raised striking after treatment expect ideological pillar. Conclusion The curative effect of Aripiprazole is superior, few adverse reaction, it can substitute the old antipsychotic.
出处
《中国健康心理学杂志》
2005年第5期344-346,共3页
China Journal of Health Psychology
